BMO Capital Downgraded Exelixis (EXEL:NASDAQ) to Market Perform

peterschreiber.media BMO Capital Markets downgraded Exelixis (NASDAQ:Excel) to outperform the market as it sees limited upside for the stock in 2025. The investment firm said it sees a balanced risk/reward for the upcoming reading of zanzalintinib in colorectal cancer, or…